BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Neurocrine Terminates Parkinson’s Deal with Voyager Following Clinical Hold

  The two companies first partnered in 2019 to develop a gene therapy treatment for Parkinson’s disease, and other neurodegenerative disorders.

  February 3, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Biotech Bay

  COVID-19 News: Vaxart Posts Phase I Data on Oral Vaccine, BMS Licenses mAb

  The vast majority of COVID-19 vaccines on the market or in development are administered through an injection, but Vaxart is attempting to develop an oral vaccine.

  February 3, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  BioSpace Global Roundup: China’s JW Therapeutics Advances CAR-T Plans

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

  February 3, 2021

   · 

  8 min read

   · 

  Alex Keown
• 

  Drug Development

  Biogen Ditches Parkinson’s Drug After Phase II Study Fails to Show Benefit

  As the therapy “did not achieve proof-of-concept” and failed to provide benefit in this study, the development of the drug has been discontinued.

  February 3, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Drug Development

  Phase III Updates: CanSino, Global Blood Therapeutics, Travere and NeurMedix

  A few companies shared some big Phase III results this week. Here’s a look.

  February 3, 2021

   · 

  2 min read

   · 

  Mark Zipkin
• 

  Drug Development

  Study Supports Delay of Second Dose of AstraZeneca’s COVID-19 Vaccine

  Although designed for two doses, primary analysis of AstraZeneca and the University of Oxford’s Phase III data for its COVID-19 vaccine found it to have 76% efficacy after the first dose.

  February 3, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  GSK and CureVac Take Aim at COVID-19 Variants with Second-Generation mRNA Vaccine

  The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.

  February 3, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  FDA Approves Merck KGaA’s Tepmetko for Aggressive Lung Cancer

  The U.S. Food and Drug Administration (FDA) granted Merck KGaA, Darmstadt, Germany’s Tepmetko (tepotinib) approval for adults with metastatic non-small cell lung cancer (NSCLC) who have a MET exon 14 skipping alteration.

  February 3, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Amgen Q4 Report: Five Halted or Killed Cancer Programs, Revenue Up 7%

  Amgen released its fourth-quarter and full-year 2020 results today and although there was good news financially, there was also news of five cancer programs that have either been halted or abandoned.

  February 3, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  FDA Hit Record Drug and Biologic Approvals in 2020, Despite Ongoing Pandemic

  For the pharmaceutical industry, the lack of face-to-face meetings caused the U.S. Food and Drug Administration to implement regulatory workarounds to stay on top of drug and biologics approvals.

  February 3, 2021

   · 

  2 min read

   · 

  Brandon May